| Document |
Document Title |
|
WO/2021/233882A1 |
This invention relates to a novel process for making alkyl 7-amino-5-methyl-[1,2,5]-oxadiazolo[3,4-b]pyridine-carboxyla
te.
|
|
WO/2021/236771A1 |
The present disclosure related to compounds that can be useful as inhibitors of PD-1, PD-Ll or the PD-1/PD-Ll interaction. Also disclosed herein are pharmaceutical compositions of that can include a compound of Formula (I), or a pharmace...
|
|
WO/2021/234084A1 |
The present invention relates to the compounds of formula (I) and pharmaceutical compositions containing these compounds. The compounds provided herein can act as maxi-K potassium channel openers, which makes them suitable for use in the...
|
|
WO/2021/233296A1 |
The present invention relates to a crystalline form of a free base of a compound of formula (A) (compound A) or a pharmaceutically acceptable salt thereof, a preparation method therefor, and use of the compound in the preparation of a me...
|
|
WO/2021/236578A1 |
Chromen-4-one derivatives, such as e.g. flavone derivatives and pharmaceutical compositions thereof are disclosed. In some instances, the compounds have increased aqueous solubility, bioavailability, and ability to cross the blood-brain-...
|
|
WO/2021/233302A1 |
Disclosed are a kind of fused ring derivatives, and specifically disclosed are compounds as shown in formula (I) and pharmaceutically acceptable salts thereof.
|
|
WO/2021/233434A1 |
A new crystal form of bictegravir sodium and a preparation method therefor. Specifically, a crystal form L1 and a crystal form L2 of bictegravir sodium and a preparation method therefor. The crystal form L1 of bictegravir sodium is simpl...
|
|
WO/2021/233884A1 |
This invention relates to a novel continuous process for making alkyl 7-amino-5-methyl- [1,2,5]-oxadiazolo[3,4-b]pyridine-carboxylate.
|
|
WO/2021/226941A1 |
The subject of the present invention is to provide a method for manufacturing a new dioxazine pigment composition that is not prone to containing impurities containing sulfur, etc. in the pigment as a final product. In addition, a new di...
|
|
WO/2021/228213A1 |
A combination comprising a tricycle compound and use thereof in the preparation of a medicament for treating HBV. The combination is a combination of a compound of formula (I) or a pharmaceutically acceptable salt thereof and any one dru...
|
|
WO/2021/227865A1 |
Disclosed are a substituted vinyl oxazole [4,5-b] pyridine salt, an application thereof as a cell membrane fluorescent marker, and a preparation method thereof by using 2-methyl oxazole [4,5-b] pyridine as a raw material. The fluorescent...
|
|
WO/2021/230512A1 |
Provided is a benzazole derivative that effectively absorbs a high-energy external light source in a UV region so as to minimize damage to organic materials inside an organic electroluminescent device, thereby contributing to a substanti...
|
|
WO/2021/228223A1 |
The present invention relates to a deuterated AKT kinase inhibitor, and in particular to a compound represented by formula I, or pharmaceutically-acceptable salts thereof. The present invention further provides a preparation method, and ...
|
|
WO/2021/228173A1 |
The present invention relates to azepine fused ring compounds and their medical uses. Specifically, the present invention relates to an azepine fused ring compound represented by the general formula (I), a preparation method therefor, a ...
|
|
WO/2021/230511A1 |
Provided is a benzazole derivative which contributes to improving substantial optical efficiency and viewing angle of an organic electroluminescent device. An organic electroluminescent device according to the present invention comprises...
|
|
WO/2021/228594A1 |
The invention relates to compounds of formula (I) wherein the variables have the meanings as defined in the specification, to compositions comprising them, to active compound combinations comprising them, and to their use for protecting ...
|
|
WO/2021/228159A1 |
Disclosed is a bridged cyclic pyrimidinone compound as represented by formula (I) or a pharmaceutically acceptable salt thereof, wherein the compound has the structure as represented by formula (I), is a completely new Lp-PLA2 inhibitor,...
|
|
WO/2021/224040A1 |
The invention relates to compounds of formula (I), and their use as herbicides. In said formula, R1 to R6 represent groups such as hydrogen, halo-gen or organic groups such as alkyl, alkenyl, alkynyl, or alkoxy; W is a bicyclic heterocyc...
|
|
WO/2021/225466A1 |
The present invention relates to a new anti-coronavirus therapeutic agent – substituted 7-hydroxy-3,4,12,12a-tetrahydro-1H-[1,4]oxazino[3,4-c]pyrido
[2,1-ƒ][1,2,4]triazine-6,8-dione for the prophylaxis and treatment of SARS-CoV-2 (COV...
|
|
WO/2021/224291A1 |
The present invention relates to tricyclic heterocycles. These heterocyclic compounds are useful as TEAD binders and/or inhibitors of YAP-TEAD and TAZ-TEAD protein-protein interaction or binding and for the prevention and/or treatment of...
|
|
WO/2021/224320A1 |
Compounds of formula (I): wherein R, X1, X2, X3, Z1, Z2, Z3, A and Ra are as defined in the description. Medicaments.
|
|
WO/2021/222353A1 |
The present disclosure relates to novel compounds for use in therapeutic treatement of a disease associated with peptidylarginine deiminases (PADs), such as peptidylarginine deiminase type 4 (PAD4). The present disclosure also relates to...
|
|
WO/2021/219088A1 |
The present invention relates to a pyrimidine-based tricyclic compound and a use thereof, and specifically, relates to a pyrimidine-based tricyclic compound and a use thereof in preparation of a drug for treating a related disease. Speci...
|
|
WO/2021/221032A1 |
The present invention addresses the problem of providing a photoelectric conversion element that exhibits excellent external quantum efficiency and responsiveness with respect to light having any wavelength among a red wavelength range, ...
|
|
WO/2021/222614A1 |
Provided herein are compounds that modulate the activity of melanoma inhibitor of apoptosis (ML-IAP) protein, compositions comprising the compounds, and methods of using the compounds and compositions comprising the compounds.
|
|
WO/2021/219100A1 |
Provided are a compound having the structure as represented by formula (I) or an optical isomer, a pharmaceutically acceptable salt, a prodrug, a deuterated form, a hydrate, and a solvate thereof, a method for preparing the compound of f...
|
|
WO/2021/219731A2 |
The invention relates to kinase inhibitors, in particular inhibitors of protein kinases including the SIK-family, CSF1R, HCK, TEK-family, BRK, ABL, KIT and/or their mutants. Although structurally similar to other bicyclic kinase inhibito...
|
|
WO/2021/216440A1 |
The present disclosure describes novel protein kinase inhibitors and methods for preparing them. The pharmaceutical compositions comprising such protein kinase inhibitors and methods of using them for treating cancer and other diseases, ...
|
|
WO/2021/214727A1 |
Cancer stem cells are responsible for tumor recurrence, distant metastasis and drug-resistance, in the vast majority of cancer patients. There exists an urgent need to identify new mitochondrial inhibitor drugs that can target and eradic...
|
|
WO/2021/216656A1 |
The present disclosure provides, in part, 5-membered heteroaryl carboxamide compounds, and pharmaceutical compositions thereof, useful for disruption of HBV core protein assembly, and methods of treating Hepatitis B (HBV) infection.
|
|
WO/2021/213317A1 |
The present invention relates to a compound represented by general formula (1) and a preparation method therefor, and use of the compound represented by general formula (1) or each isomer, each crystalline form, a pharmaceutically accept...
|
|
WO/2021/215514A1 |
A compound of formula (1), and a labeled biomaterial having the same. Z1 and Z2 represent specific six-membered rings. However, at least one of Z1 and Z2 is a benzene ring having a specific substituent at the ortho position relative to...
|
|
WO/2021/211741A1 |
Compounds having the structure of Formula (I) or pharmaceutically acceptable isomers, racemates, hydrates, solvates or salts thereof, where A, R1, R2a, R2b, R2c and R3 are as defined herein, are useful in the modulation of IL-12, IL-23 a...
|
|
WO/2021/208850A1 |
Disclosed are a nitroimidazole derivative, a preparation method therefor and use thereof. The compound has the following formula (I).
|
|
WO/2021/208963A1 |
Disclosed herein is a compound of Formula (I) for inhibiting both Bcl-2 wild type and mutated Bcl-2, in particular, Bcl-2 G101V and D103Y, and a method of using the compound disclosed herein for treating dysregulated apoptotic diseases.
|
|
WO/2021/207453A1 |
The present description relates to compounds of Formula (I), forms, and pharmaceutical compositions thereof and methods of using such compounds, forms, or compositions thereof for treating or ameliorating Huntington's disease.
|
|
WO/2021/205448A1 |
The present invention is directed to a co-crystal comprising a compound of formula (I) and an antioxidant, as well as to formulations comprising said co-crystals. The invention also discloses the use of an antioxidant to improve the stab...
|
|
WO/2021/204159A1 |
The present disclosure provides compounds represented by Formula (I), or a pharmaceutically acceptable salt thereof, wherein Ra, Rb, Rc, Rd, V, Q, T, n, p, q, r and s are as defined as set forth in the specification. The present disclosu...
|
|
WO/2021/204252A1 |
The present application falls within the field of medical chemistry, and relates to a tetracyclic compound as a hepatitis B surface antigen inhibitor. The present application specifically relates to a compound of formula I, and a stereoi...
|
|
WO/2021/207308A1 |
The present disclosure provides compounds of formula (I) and methods useful for inhibiting SARM1 and/or treating and/or preventing axonal degeneration.
|
|
WO/2021/198213A1 |
The invention relates to compounds which are suitable for use in electronic devices, and to electronic devices, in particular organic electroluminescent devices, containing said compounds.
|
|
WO/2021/203011A1 |
Disclosed herein are kinase inhibitory compounds, such as a receptor-interacting protein-1 (RIP1) kinase inhibitor compounds, as well as pharmaceutical compositions and combinations comprising such inhibitory compounds. The disclosed com...
|
|
WO/2021/197499A1 |
Disclosed is a class of octahydropyrazinodiazanaphthyridine dione compounds, and specifically disclosed are a compound as shown in formula (III) and a pharmaceutically acceptable salt thereof.
|
|
WO/2021/197452A1 |
The present invention relates to a crystal form of the free alkali of nitrogen-containing aromatic derivatives. In particular, the present invention relates to a crystal form of the compound represented by the general formula (I), its pr...
|
|
WO/2021/194914A1 |
Disclosed are compounds of Formula (I) or a salt thereof, wherein Ring A is a carbon-linked ring; and Ring A, R1, and n are defined herein. Also disclosed are methods of using such compounds to inhibit Helios protein, and pharmaceutical ...
|
|
WO/2021/195278A1 |
The present disclosure is concerned with 9-hydroxy-6-(pyrrolidin-2-yl)-3,4-dihydro-2H-pyrazino[ 1,2-c]pyrimidine- 1, 8-dione compounds for the treatment of various viral infections such as, for example, influenza virus. This abstract is ...
|
|
WO/2021/191872A1 |
The present invention relates to heteroaryl-substituted macrocyclic compounds and prodrugs thereof, and pharmaceutically acceptable salts, solvates, and polymorphs thereof, and the use of such compounds as a medicament, in particular in ...
|
|
WO/2021/190417A1 |
The present invention provides a novel aminopyrimidine compound as a fourth-generation EGFR (T790M/C797S mutation) selective inhibitor, a pharmaceutical composition comprising the compound, an intermediate useful for preparing the compou...
|
|
WO/2021/194772A1 |
Methods are disclosed including methods for crystallizing a material such as a drug. An example method may include combining a nucleation initiator, a surfactant solution, and an amorphous form of a drug to form a drug precursor dispersi...
|
|
WO/2021/190727A1 |
The invention provides novel compounds having the general formula (I) wherein R1, R2, R3a, R3b, R4, A1, A2, A3, A4, A5, A6, B1, B2, B3, B4, and L are as described herein, compositions including the compounds and methods of using the comp...
|
